Overview: Copper Test (Blood)Introduction: The Copper Test (Blood) measures copper levels in blood to diagnose Wilson's disease or copper deficiency, causing liver or neurological symptoms. Aligned with 2023 AASLD guidelines, it uses chromatography for high sensitivity, aiding in metabolic screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in biochemistry for patients with suspected copper metabolism disorders.
Other Names: Copper Serum Assay, Copper Metabolism Test.
FDA Status: Laboratory-developed test (LDT), meeting biochemistry standards for diagnostic accuracy.
Historical Milestone: Copper testing began in the 1950s with Wilson's disease research. Blood-based assays emerged in the 1970s, and by the 2000s, inductively coupled plasma-mass spectrometry improved accuracy.
Purpose: Diagnoses Wilson's disease or copper deficiency, guides treatment, and monitors copper levels in patients with liver or neurological symptoms.
Test Parameters: 1. Copper
Pretest Condition: Fasting for 10-12 hours required to stabilize copper levels. Collect serum or plasma after overnight fasting. Report symptoms like liver dysfunction or tremors, and list medications like chelating agents.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document liver dysfunction, neurological symptoms, or family history of Wilson's disease. Include current medications, especially chelating agents or zinc.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for copper-lowering or supplementation therapy.
Procedural Considerations: Uses chromatography (e.g., ICP-MS) to measure copper levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or inflammation may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Abnormal copper levels confirm Wilson's disease or deficiency, prompting chelation or supplementation. Normal levels may require urine testing.
Specialist Consultation: Consult a hepatologist for result interpretation. A neurologist referral is advised for neurological symptoms.
Additional Supporting Tests: 24-hour urine copper test, ceruloplasmin test, or liver biopsy to confirm Wilson's disease or deficiency.
Test Limitations: Results may be affected by acute conditions. Clinical correlation with urine tests is required.
References: AASLD Wilson's Disease Guidelines, 2023; Hepatology, Roberts EA, 2022.
